These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16484997)

  • 1. Between a rock and a hard place?
    Whitty A; Kumaravel G
    Nat Chem Biol; 2006 Mar; 2(3):112-8. PubMed ID: 16484997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent applications of protein crystallography and structure-guided drug design.
    Williams SP; Kuyper LF; Pearce KH
    Curr Opin Chem Biol; 2005 Aug; 9(4):371-80. PubMed ID: 16006182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein-protein interactions as targets for small molecule drug discovery.
    Fry DC
    Biopolymers; 2006; 84(6):535-52. PubMed ID: 17009316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC
    Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging classes of protein-protein interaction inhibitors and new tools for their development.
    Pagliaro L; Felding J; Audouze K; Nielsen SJ; Terry RB; Krog-Jensen C; Butcher S
    Curr Opin Chem Biol; 2004 Aug; 8(4):442-9. PubMed ID: 15288255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
    Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
    Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
    [No Abstract]   [Full Text] [Related]  

  • 10. Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery.
    Evdokimov AG; Pokross M; Walter R; Mekel M; Cox B; Li C; Bechard R; Genbauffe F; Andrews R; Diven C; Howard B; Rastogi V; Gray J; Maier M; Peters KG
    Acta Crystallogr D Biol Crystallogr; 2006 Dec; 62(Pt 12):1435-45. PubMed ID: 17139078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large-scale computational approach to drug repositioning.
    Li YY; An J; Jones SJ
    Genome Inform; 2006; 17(2):239-47. PubMed ID: 17503396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.
    Arkin MR; Wells JA
    Nat Rev Drug Discov; 2004 Apr; 3(4):301-17. PubMed ID: 15060526
    [No Abstract]   [Full Text] [Related]  

  • 14. Structure-based development of target-specific compound libraries.
    Orry AJ; Abagyan RA; Cavasotto CN
    Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structure-based approach to drug discovery; crystallography and implications for the development of antiparasite drugs.
    Hunter WN
    Parasitology; 1997; 114 Suppl():S17-29. PubMed ID: 9309766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-protein interactions as targets for small-molecule therapeutics in cancer.
    White AW; Westwell AD; Brahemi G
    Expert Rev Mol Med; 2008 Mar; 10():e8. PubMed ID: 18353193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
    Popov VM; Yee WA; Anderson AC
    Proteins; 2007 Feb; 66(2):375-87. PubMed ID: 17078091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for targeting protein-protein interactions with synthetic agents.
    Yin H; Hamilton AD
    Angew Chem Int Ed Engl; 2005 Jul; 44(27):4130-63. PubMed ID: 15954154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoinhibited proteins as promising drug targets.
    Peterson JR; Golemis EA
    J Cell Biochem; 2004 Sep; 93(1):68-73. PubMed ID: 15352163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.